Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR604 injection in hemophilia A/B and congenital factor VII deficiency (Phase I/II)
ChiCTR2500110665Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SR604 in hemophilia A, hemophilia B (HB) and congenital factor VII deficiency (6 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Part B/Part C: Treated total annualized bleeding rate (ABR), Part A: Safety and Immunogenicity – Incidence of AEs/SAEs/AESIs and 2 more. Started Oct 2025; status: completed.
02
Drugs
SR604
03
Conditions
hemophilia Ahemophilia B (HB)congenital factor VII deficiency
Beyond the preview
Go deeper on ChiCTR2500110665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110665.